Dr. Gerald Kovacs has been appointed scientific director at ABL, Inc. Dr. Kovacs will lead the company’s scientific operations supporting U.S. government and commercial preclinical programs and oversee the continued expansion of its clinical testing capabilities.
Dr. Kovacs has more than 20 years of experience in biomedical research. Most recently he served as scientific director for the Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures at the Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (HHS). While at BARDA, Dr. Kovacs directed a $5.6 billion portfolio of more than 80 vaccine and therapeutic projects spanning preclinical to Phase IV trials. In 2013, Dr. Kovacs was honored by the U.S. Department of Health and Human Services with the Secretary’s Award for Distinguished Service for obtaining FDA approval of two biodefense products. He also designed and implemented the BARDA CRO Network.